| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P50 | author | Charles Hendricks Brown | Q37367747 |
| Robert D. Gibbons | Q46996511 | ||
| P2093 | author name string | John Davis | |
| J John Mann | |||
| Kwan Hur | |||
| P2860 | cites work | Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine | Q24607720 |
| Methods for synthesizing findings on moderation effects across multiple randomized trials | Q28742658 | ||
| Integrative data analysis: the simultaneous analysis of multiple data sets | Q33457534 | ||
| Missing Data in Longitudinal Trials - Part B, Analytic Issues | Q33492294 | ||
| The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults | Q34242471 | ||
| Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial | Q34341755 | ||
| The internal struggle between the wish to die and the wish to live: a risk factor for suicide | Q34456093 | ||
| ACNP Task Force report on SSRIs and suicidal behavior in youth | Q36327813 | ||
| Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants | Q37246423 | ||
| The intermediate endpoint effect in logistic and probit regression. | Q40127940 | ||
| Prospective study of clinical predictors of suicidal acts after a major depressive episode in patients with major depressive disorder or bipolar disorder | Q40492340 | ||
| Estimating drug effects in the presence of placebo response: causal inference using growth mixture modeling | Q41874724 | ||
| Familial pathways to early-onset suicide attempt: risk for suicidal behavior in offspring of mood-disordered suicide attempters | Q51953509 | ||
| STAR*D: what have we learned? | Q79700849 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | suicide | Q10737 |
| placebo | Q269829 | ||
| fluoxetine | Q422244 | ||
| suicidal ideation | Q944142 | ||
| suicide prevention | Q3298118 | ||
| suicide risk | Q47319077 | ||
| P304 | page(s) | 580-7 | |
| P577 | publication date | 2012-06-01 | |
| P1433 | published in | JAMA Psychiatry | Q635830 |
| P1476 | title | Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine | |
| P478 | volume | 69 |
| Q36756410 | A 3-year longitudinal study examining the effect of resilience on suicidality in veterans. |
| Q42697087 | A 6-Month Open-Label Extension Study of Vortioxetine in Pediatric Patients with Depressive or Anxiety Disorders |
| Q44339425 | A Prospective Study of Antidepressant Adherence and Suicidal Ideation Among Adults |
| Q34625128 | A naturalistic study of suicidal adolescents treated with an SSRI: suicidal ideation and behavior during 3-month post-hospitalization period |
| Q24606269 | A review of the suitability of duloxetine and venlafaxine for use in patients with depression in primary care with a focus on cardiovascular safety, suicide and mortality due to antidepressant overdose |
| Q37284703 | Accelerated Intermittent Theta Burst Stimulation for Suicide Risk in Therapy-Resistant Depressed Patients: A Randomized, Sham-Controlled Trial |
| Q35945063 | Acute behavioral interventions and outpatient treatment strategies with suicidal adolescents. |
| Q99545980 | Adaptation of evidence-based suicide prevention strategies during and after the COVID-19 pandemic |
| Q47288329 | Advancing the Study of Adolescent Substance Use Through the Use of Integrative Data Analysis. |
| Q34989561 | An association between initiation of selective serotonin reuptake inhibitors and suicide - a nationwide register-based case-crossover study |
| Q38044018 | An update on antidepressant use and suicidality in pediatric depression |
| Q48075180 | Antidepressant Regulatory Warnings, Prescription Patterns, Suicidality and Other Aggressive Behaviors in Major Depressive Disorder and Anxiety Disorders. |
| Q34399552 | Antidepressant drugs and the risk of suicide in children and adolescents |
| Q35032482 | Antidepressant treatment and suicide attempts and self-inflicted injury in children and adolescents |
| Q37522908 | Antidepressants and suicide attempts in children |
| Q34470905 | Antidepressants and the risk of suicide in young persons – prescription trends and toxicological analyses |
| Q41814367 | Antidepressants are an Important Part of Treating Depression |
| Q44095280 | Antidepressants in the Treatment of Depression: The Clinician and the Controversy |
| Q88164743 | Antidepressive agents and suicidal tendencies |
| Q90435436 | Association of Antidepressant Use With Adverse Health Outcomes: A Systematic Umbrella Review |
| Q37197216 | Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments |
| Q39406995 | Cardiovascular fitness in early adulthood and future suicidal behaviour in men followed for up to 42 years. |
| Q33774659 | Changes in antidepressant use by young people and suicidal behavior after FDA warnings and media coverage: quasi-experimental study |
| Q40838252 | Comparing episodes of antidepressants use with intermittent episodes of no use: A higher relative risk of suicide attempts but not of suicide at young age. |
| Q30406130 | Concurrent trajectories of change in adolescent and maternal depressive symptoms in the TORDIA study |
| Q53447300 | Decreased suicide rates in recent antidepressant clinical trials |
| Q58763102 | Demographic and clinical factors associated with different antidepressant treatments: a retrospective cohort study design in a UK psychiatric healthcare setting |
| Q36801219 | Do antidepressant medications work? |
| Q38221283 | Do antidepressants make children and adolescents suicidal? |
| Q89964557 | Duty to Warn: Antidepressant Black Box Suicidality Warning Is Empirically Justified |
| Q92622614 | Délai d’action de la fluoxétine chez les enfants souffrant de dépression |
| Q30491758 | Effects of vilazodone on suicidal ideation and behavior in adults with major depressive disorder or generalized anxiety disorder: post-hoc analysis of randomized, double-blind, placebo-controlled trials |
| Q35576952 | Electronic protocol for suicide risk management in research participants |
| Q22242979 | Evidence-based psychosocial treatments for self-injurious thoughts and behaviors in youth |
| Q37059670 | Fluoxetine increases suicide ideation less than placebo during treatment of adults with minor depressive disorder |
| Q30588879 | Identifying suicidal behavior among adolescents using administrative claims data |
| Q39295151 | Impact of escitalopram on vagally mediated cardiovascular function in healthy participants: implications for understanding differential age-related, treatment emergent effects |
| Q34177760 | Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety. |
| Q93606471 | In this issue |
| Q30587472 | Integrative Data Analysis in Clinical Psychology Research |
| Q90106477 | Item-based analysis of the effects of duloxetine in depression: a patient-level post hoc study |
| Q38809056 | KETAMINE: A POTENTIAL RAPID-ACTING ANTISUICIDAL AGENT? |
| Q92517891 | Ketamine as augmentation for the treatment of major depression and suicidal risk in advanced cancer: Case report |
| Q47688167 | Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial |
| Q37705296 | Life events: a complex role in the timing of suicidal behavior among depressed patients |
| Q37266988 | Lower anxiogenic effects of serotonin agonists are associated with lower activation of amygdala and lateral orbital cortex in adolescent male rats |
| Q59812788 | Magnetic seizure therapy reduces suicidal ideation and produces neuroplasticity in treatment-resistant depression |
| Q38049859 | Management of Psychotropic Medication Side Effects in Children and Adolescents |
| Q53414337 | Near Real-time Surveillance for Consequences of Health Policies Using Sequential Analysis |
| Q36597645 | Nonpsychotic Mental Disorders in Teenage Males and Risk of Early Stroke: A Population-Based Study |
| Q91893886 | Omega-3 Fatty Acids as a Treatment for Pediatric Depression. A Phase III, 36 Weeks, Multi-Center, Double-Blind, Placebo-Controlled Randomized Superiority Study |
| Q37112065 | Outside the Black Box: Re-assessing Pediatric Antidepressant Prescription |
| Q47998122 | Pharmacogenetics of citalopram-related side effects in children with depression and/or anxiety disorders |
| Q24186543 | Pharmacological interventions for self-harm in adults |
| Q37047635 | Pharmacotherapy for Pediatric Generalized Anxiety Disorder: A Systematic Evaluation of Efficacy, Safety and Tolerability |
| Q21132322 | Preclinical evidence of rapid-onset antidepressant-like effect in Radix Polygalae extract |
| Q89968489 | Prefrontal Cortical Reactivity and Connectivity Markers Distinguish Youth Depression from Healthy Youth |
| Q37455370 | Prevalence, correlates, and treatment of lifetime suicidal behavior among adolescents: results from the National Comorbidity Survey Replication Adolescent Supplement |
| Q33849384 | Preventing internalizing symptoms among Hispanic adolescents: a synthesis across Familias Unidas trials |
| Q37416063 | Protecting adolescents from self-harm: a critical review of intervention studies |
| Q30234967 | Psychiatric Emergencies: Assessing and Managing Suicidal Ideation |
| Q52855244 | Psychopharmaceuticals for treatment of suicidal patients and for suicide prevention |
| Q38049864 | Psychopharmacologic Treatment of Obesity and Eating Disorders in Children and Adolescents |
| Q55342446 | Regional Variations in Suicide and Undetermined Death Rates among Adolescents across Canada. |
| Q28245269 | Risk of suicidal behavior with antidepressants in bipolar and unipolar disorders |
| Q35036979 | SSRI versus bupropion effects on symptom clusters in suicidal depression: post hoc analysis of a randomized clinical trial |
| Q48063920 | SUICIDAL DEPRESSED PATIENTS RESPOND LESS WELL TO ANTIDEPRESSANTS IN THE SHORT TERM. |
| Q28548023 | Selective Serotonin Reuptake Inhibitors and Violent Crime: A Cohort Study |
| Q47322500 | Self-Rated Depression Severity Relative to Clinician-Rated Depression Severity: Trait Stability and Potential Role in Familial Transmission of Suicidal Behavior |
| Q36004533 | Should antidepressant medication be used in the elderly? |
| Q33836848 | Suicidal behaviour in mood disorders--who, when, and why? |
| Q92746028 | Suicidal ideation and behavior in adults with major depressive disorder treated with vortioxetine: post hoc pooled analyses of randomized, placebo-controlled, short-term and open-label, long-term extension trials |
| Q36635612 | Suicide Behavior Before and After the Start with Antidepressants: A High Persistent Risk in the First Month of Treatment Among the Young |
| Q34494779 | Suicide and suicidal behaviour |
| Q36478660 | Suicide or accident? A psychological autopsy study of suicide in youths under the age of 16 compared to deaths labeled as accidents |
| Q37190246 | Suicide-related events in young people following prescription of SSRIs and other antidepressants: a self-controlled case series analysis |
| Q33763721 | Temporal trends in antidepressant prescribing to children in UK primary care, 2000-2015. |
| Q35913626 | Testing moderation in network meta-analysis with individual participant data |
| Q26849351 | The 5-HT deficiency theory of depression: perspectives from a naturalistic 5-HT deficiency model, the tryptophan hydroxylase 2Arg439Hisknockin mouse |
| Q64068264 | The FDA “Black Box” Warning on Antidepressant Suicide Risk in Young Adults: More Harm Than Benefits? |
| Q92350285 | The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): a randomised, double-blind, placebo-controlled, multicentre clinical trial |
| Q34504812 | The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): study protocol for a randomised control trial |
| Q37079049 | The drugs don't work? antidepressants and the current and future pharmacological management of depression |
| Q41989162 | The ethics of prescription of placebos to patients with major depressive disorder |
| Q47878353 | The impact of 5-HTTLPR on acute serotonin transporter blockade by escitalopram on emotion processing: preliminary findings from a randomised, crossover fMRI study |
| Q38584872 | The neurobiology of suicide |
| Q44217155 | The pharmacoepidemiology of selective serotonin reuptake inhibitors for children and adolescents in Canada from 2005 to 2009: a database analysis |
| Q33744415 | The statistics of suicide |
| Q92622525 | Time-to-effect of fluoxetine in children with depression |
| Q38089038 | Treating Depression With Antidepressants: Drug-Placebo Efficacy Debates Limit Broader Considerations |
| Q31151206 | Two-Year Impact of Prevention Programs on Adolescent Depression: an Integrative Data Analysis Approach |
| Q38760853 | Use of Prescription Medication by Individuals Who Died by Suicide in Northern Ireland |
| Q39077689 | Use of antidepressants and the risk of cardiovascular and cerebrovascular disease: a meta-analysis of observational studies |
| Q38109851 | When do you prescribe antidepressants to depressed children? |
| Q88305363 | [No high-level evidence for the suicide prevention through antidepressants or clozapine] |
Search more.